Replies to post #437453 on Anavex Life Sciences Corp (AVXL)

[abew4me]

First time leading a company...and yet, he single-handedly saved it from BK and is now debt-free with $150 Million in the bank

First time doing trials...and yet, every trial has been a success

First time trying to commercialize...and yet, we are 6-12 months away from commercializing A2-73 for Rett

First time dealing with regulators...and yet, he was smart enough to hire the top-dog from the FDA to ensure our approval process

First time dealing directly with shareholders...as it turns out, the largest shareholders of AVXL are institutions.

Quite an accomplishment, no?

[attilathehunt]

Bingo!!! Bingo!!!! Bingo!!!!

Right on!!!!


Someone else sees the light...Unfortunately those that see the light are not on the Board!

[nidan7500]

Name one person who has already done what you say it takes in AD-CNS ...HUH,

-First time leading a company
-First time doing trials
-First time trying to commercialize
-First time dealing with regulators
-First time dealing directly with shareholders
-etc. etc. etc.

guess what...we (AVXL+staff) are doing pharma-clinical-bio-WW -trials which have never been successfully completed by anyone-anywhere. BTW, intellectual integrity matters...ALOT around here....

[BIOChecker4]

“Sometimes the job is just too big.”

I have been saying for years that Missling has risen to his level of incompetence. Everyone knows this except an handful of loud WGTs. Even some of them have begun to realize the truth.

It is obvious to anyone who looks objectively that Missling is an autocrat who marches to the beat of his own drummer and listens to no one, including and especially shareholders. This is one reason Anavex will never partner with a big biopharma company and vice versa. Missling simply cannot and will not give up or even share control.

Here I will digress: As to the comment in some recent posts that Missling has done a brilliant job on the financing side, having put $150 million in the bank, it does not take a financial genius to sign a ATM deal with a vulture investor and start diluting to your heart’s content. The real trick, the trick that actually requires financial acumen, is to court, work with, and convince serious biotech investors of the veracity of your science, your results and your business strategy, so that they will finance you and support you. But of course Missling does not want to have actual institutional investors owning his stock because, for among other reasons, they do too much due diligence and they hold CEOs accountable for their results (or lack of).

Good luck and DOG bless,